Helicobacter pylori proteins and gastric mucosal surface

Helicobacter pylori is a microaerophilic, Gram-negative bacterium that specifically colonizes the human gastric mucosa, where it serves as a primary causative agent of chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma (StatPearls, 2023). The target system described encompasses a complex interplay between bacterial enzymes, such as urease, which neutralizes stomach acid by converting urea into ammonia, and virulence factors like VacA (vacuolating cytotoxin) and CagA (cytotoxin-associated gene A) that disrupt host cell integrity and signaling (Nature Reviews Disease Primers, 2017). Adhesion to the mucosal surface is mediated by bacterial adhesins like BabA and SabA, which recognize specific carbohydrate receptors on the gastric epithelium (PubMed, 2021). Therapeutic strategies typically involve multi-drug regimens, including antibiotics (e.g., amoxicillin, clarithromycin) to target bacterial processes and proton pump inhibitors (PPIs) to raise gastric pH, thereby facilitating mucosal healing and enhancing antibiotic efficacy (NIH, 2022). Eradication of H. pylori is a critical clinical objective for preventing long-term complications, including MALT lymphoma and gastric cancer.

Other names

Helicobacter pylori virulence factorsGastric mucosal barrierH. pylori-host interfaceGastric mucosal surface components

Antibiotics inhibit bacterial cell wall, protein, or DNA synthesis; PPIs and potassium-competitive acid blockers (PCABs) inhibit the host gastric H+/K+ ATPase to raise pH; bismuth compounds provide mucosal protection and direct antimicrobial activity.